Low impact
AstraZeneca's experimental obesity pill achieved 11.8% weight loss in mid-stage trial, targeting the growing weight-loss combination drug market.
BLOOMBERG06/09, 05:01 AM
Related assets
Coming up for AZN
Explore next
Latest AZN news
Jin1008/17, 07:48 PM
Jin1008/17, 01:48 PM
Jin1008/05, 07:04 PM
Astrazeneca and Bristol Myers Squibb have no ongoing discussions regarding a potential transaction.